drugset
Drugs / Fluorine F 18 Flotufolastat
last change Feb 2026 re-read 3 minutes ago

Fluorine F 18 Flotufolastat

also known as flotufolastat F 18

Diagnostic / imaging agent

Investigated by
Blue Earth Diagnostics · Jonsson Comprehensive Cancer Center

Trials 1

today NCT07185165 · Ph 2
20262027202820292030203120322033203420352036
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07185165 Oct 2025 → Oct 2035 expected prostate carcinoma Jonsson Comprehensive Cancer Center Recruiting No outcome recorded

Press releases naming this drug 20 releases

DateIssuerRelease
2026-02-27 Blue Earth Diagnostics Blue Earth Diagnostics Announces Positive Results from Head-to-Head Comparator Study of POSLUMA® (Flotufolastat F 18) and Piflufolastat F 18 Urinary Bladder Radioactivity in Men with Biochemical Recurrence of Prostate Cancer blueearthdiagnostics.com ↗
2026-02-18 Blue Earth Diagnostics Blue Earth Diagnostics to Highlight New POSLUMA® (Flotufolastat F 18) Study Results in Prostate Cancer at the 2026 ASCO Genitourinary Symposium (ASCO GU) blueearthdiagnostics.com ↗
2024-10-01 Blue Earth Diagnostics Results of POSLUMA® (Flotufolastat F 18) Performance in Recurrent Prostate Cancer After Radical Prostatectomy at Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO blueearthdiagnostics.com ↗
2024-09-24 Blue Earth Diagnostics Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting blueearthdiagnostics.com ↗
2024-07-30 Blue Earth Diagnostics Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA® (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer blueearthdiagnostics.com ↗
2024-06-10 Blue Earth Diagnostics Blue Earth Diagnostics Highlights Results of Studies Evaluating Impact of Urinary Activity on Image Interpretation and Performance of POSLUMA® (Flotufolastat F 18) and 18F-Flotufolastat PET in Prostate Cancer blueearthdiagnostics.com ↗
2024-05-29 Blue Earth Diagnostics Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting blueearthdiagnostics.com ↗
2024-05-08 Blue Earth Diagnostics Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development blueearthdiagnostics.com ↗
2024-01-25 Blue Earth Diagnostics This press release is for US audiences only. Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU blueearthdiagnostics.com ↗
2024-01-16 Blue Earth Diagnostics Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU) blueearthdiagnostics.com ↗
2023-11-28 Blue Earth Diagnostics Blue Earth Diagnostics Announces Publication of Post-hoc Analysis Evaluating Impact of Urinary Activity on Image Interpretation of POSLUMA® (Flotufolastat F 18) PET in Prostate Cancer. blueearthdiagnostics.com ↗
2023-10-03 Blue Earth Diagnostics Additional Results of POSLUMA® (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO blueearthdiagnostics.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as fluorine F 18 flotufolastat “To evaluate the accuracy of fluorine F 18 flotufolastat (flotufolastat F 18) compared with prostate biopsy to determine treatment success following focal therapy of the prostate.” NCT07185165 ↗
1

NCT07185165 ↗
Known as flotufolastat F 18 “Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells.” NCT07185165 ↗
Modality Diagnostic / imaging agent “Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells.” NCT07185165 ↗
Route Intravenous “Patients receive flotufolastat F-18 intravenously (IV).” NCT07185165 ↗